EGFR and non-small cell lung carcinoma: Inspiringly, the results of the IMpower-150 trial and the ORIENT-31 trial indicated that the combined treatment regimen of immunotherapy, chemotherapy and anti-angiogenesis agents might be effective in EGFR-mutant advanced NSCLC patients [7–9], while the potential mechanisms warranted further explorations.